Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks […]
This article gives a good summary of the use of genetic tests to indicate your risk of developing certain cancers, as well as the down sides of genetic testing. Genetic tests can determine whether you are at risk of developing cancer by finding mutations in a person’s genes. The risk of developing cancer increases if […]
This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]
In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Houston, Texas describes how to treat a kidney mass in patients with VHL disease. VHL (von Hippel-Lindau) disease is very rare and affects about 1 in 35,000 people. Between 30 to 70% of people with VHL disease have kidney masses. If the mass […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
